Tandem Diabetes Care, Inc.: Business Overview, Financials & Competitive Analysis
Tandem Diabetes Care, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). High-growth diabetes technology leader with proprietary closed-loop algorithms, strong clinical positioning, and expanding international footprint positioned for sustained market share gains. Tandem's 2024 revenue was $940.20 million, an increase of 25.74% compared to the previous year's $747.72 million. The company is demonstrating strong market traction with profitable operations.
What is Tandem Diabetes Care, Inc.'s industry? Tandem Diabetes Care, Inc. (tandemdiabetes.com) operates in Medical Device Manufacturing - Insulin Delivery Systems & Diabetes Technology. AskCyborg classifies Tandem Diabetes Care, Inc. under Medical Device Manufacturing - Insulin Delivery Systems & Diabetes Technology in its company registry.
Tandem Diabetes Care is an insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems for diabetes management. The company's flagship products include the ...
Cyborg Score thesis
High-growth diabetes technology leader with proprietary closed-loop algorithms, strong clinical positioning, and expanding...
Read the full analyst-debate transcript →Get the Latest Tandem Diabetes Care, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTandem Diabetes Care, Inc. Overview
Pro stress-test →Tandem Diabetes Care is an insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems for diabetes management. The company's flagship products include the t:slim X2 insulin pump and the Tandem Mobi system, which feature proprietary Control-IQ+ technology that uses predictive algorithms to automate insulin delivery.
Strategic Profile
Pro stress-test →Tandem is the number one recommended insulin pump brand by people living with diabetes for multiple years, having established significant brand loyalty and trust. The company leverages interoperable technology with major CGM manufacturers like Dexcom and Abbott, positioning itself as a comprehensive diabetes management platform rather than a standalone device maker.
Competitive Landscape
Pro stress-test →Tandem faces competition from Medtronic (dominant market share with Guardian 4 sensor), Insulet (Omnipod tubeless alternative), and emerging players like Beta Bionics. However, Tandem maintains analyst consensus of "Buy" with 12-month price target of $24.35 representing 24.65% upside from latest prices. Tandem's proprietary algorithms and user-centric design differentiate it in this competitive space.
Industry Context
Tandem Diabetes Care, Inc. operates in Medical Device Manufacturing - Insulin Delivery Systems & Diabetes Technology.
Key facts
Founded: 2006 · Headquarters: San Diego, United States · Employees: 2,650 · Revenue: $940.2M · Market cap: $1.3B